Patients with Acute Ischemic Stroke
Conditions
Interventions
Control Group:Piracetam injection (50mL:10g), added to 250mL of 5% glucose injection for intravenous drip, once daily for 4 weeks
Trial Group:Piracetam injection (50mL:10g), added to 250mL of 5% glucose injection for intravenous drip, once daily for 4 weeks, combined with Ginkgo biloba tablets (each tablet contains total flavono
Sponsors
Chongqing Yubei District Traditional Chinese Medicine Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years 2. Meets diagnostic criteria in Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke; confirmed as first-ever acute ischemic stroke by brain MRI 3. Onset within 72 hours 4. Cognitive impairment present, Montreal Cognitive Assessment (MoCA) score < 26 5. Written informed consent signed by patient or legal representative
Exclusion criteria
Exclusion criteria: 1. Transient ischemic attack (TIA) 2. Stroke caused by other reasons such as cardioembolism or vascular malformations 3. Coexisting intracranial infection, malignant tumors, or severe hepatic/renal insufficiency (ALT/AST > 2x upper limit of normal, Scr > 133 µmol/L) 4. Allergy to piracetam or Ginkgo biloba leaves 5. Pregnant or lactating women 6. Severe psychiatric disorders or inability to cooperate with cognitive function assessment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive Function;Serum Inflammatory Markers (IL-6, hs-CRP, TNF-a); | — |
Secondary
| Measure | Time frame |
|---|---|
| Neurological Deficit;Liver and Renal Function (ALT, AST, Serum Creatinine, Urea Nitrogen); | — |
Countries
China
Contacts
Public ContactChen Gang
Chongqing Yubei District Traditional Chinese Medicine Hospital
Outcome results
None listed